References
- Powderly WG. Therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1992; 14 (Si): S54–59.
- Zuger A, Schuster M, Simberkoff MS, Rahal JJ, Holzman RS. Maintenance amphotericin B for cryptococcal meningitis in the acquired immunodeftciency syndrome (AIDS). Ann Intern Med 1988; 109: 592–593.
- Casadevall A, Spitzer ED, Webb D, Rinaldi MG. Susceptibili-ties of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother 1993; 37: 1383–1386.
- Khanlou H, Salmon D, Paugam A, et al. Factors of failure in fluconazole (FCZ) therapy of oral and esophageal candidiasis in HIV-infected patients (pts). In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1995. Washing-ton, DC: American Society for Microbiology, 1995: abstract E62.
- Velez JD, Allendorfer R, Luther M, Rinaldi MG, Graybill JR Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis 1993; 168: 508–510.
- Bartroli J, Tunno E, Alguero M, et al. Synthesis and antifungal activity of new azole derivatives containing on N-acylmorpho-line ring. J Med Chem 1995; 38: 3918–3932.
- Bomay-Llinares FJ, Torres-Rodriguez JM. Anticryptococcal meningitis activity of a new azole derivative (UR-9746) in a murine model. In: Program and Abstracts of the 35th Inter-science Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1995. Washington, DC: Ameri-can Society for Microbiology, 1995: abstract F86.
- National Committee for Clinical Laboratory Standards. Refer-ence method for broth dilution antifungal susceptibility testing for yeasts: proposed standard M27-P. National Committee for Clinical Laboratory Standards: Villanova, PA, 1992.
- Clemons KY, Stevens DA. Efficacy of UR-9746 and UR-9751 against coccidioidomycosis. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1995. Washing-ton, DC: American Society of Microbiology, 1995: abstract B70.
- Stevens DA, Devine MJ, Martinez M, Aristizabal B. In vitro antifungal activity of novel azole derivatives with a morpholine ring, UR-9746 (U46) and UR-9751 (UR51); comparison with fluconazole (F). In: Program and Abstracts of the 35th Inter-science Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1995. Washington, DC: Ameri-can Society of Microbiology, 1995: abstract F85.
- Improvisi L, Garcia-Hermoso D, Provost F, Dupont B. Evalu-ation of two novel antifungal agents, UR-9746 and UR-9751 in the treatment of experimental murine histoplasmosis. In: Pro-gram and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1995. Washington, DC: American Society of Micro-biology, 1995: abstract F89.
- Bomay-Llinares FJ, Mayol-Belda MS, Onrubia-Pintado J, Tor-res-Rodriguez JM. Murine cryptococcosis. Tissular damage decrease after treatment with UR-9746. In: Program and Ab-stracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1995. Washington, DC: American Society for Microbiology, 1995: abstract F88.